Generic Name and Formulations:
Famotidine 20mg, 40mg; tabs.
Bausch Health Companies Inc.
Indications for PEPCID:
Active duodenal ulcer. Maintenance of healed duodenal ulcer. Active benign gastric ulcer. Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas). Gastroesophageal reflux disease (GERD). Esophagitis due to GERD.
Duodenal ulcer: 40mg once daily at bedtime or 20mg twice daily for 4–8 weeks. Maintenance: 20mg once daily at bedtime. Benign gastric ulcer: 40mg once daily at bedtime for up to 8 weeks. Hypersecretory conditions: Initially 20mg every 6hrs; individualize. GERD symptoms: 20mg twice daily for up to 6 weeks. Esophagitis: 20–40mg twice daily for up to 12 wks (see full labeling).
Individualize; adjust based on response. <1yr: not recommended. 1–16yrs: Peptic ulcer: Initially 0.5mg/kg per day at bedtime or in 2 divided doses; max 40mg/day. GERD: Initially 1mg/kg per day divided in 2 doses; max 40mg twice daily.
Symptomatic response does not preclude gastric malignancy. Moderate-to-severe renal insufficiency (CrCl <50mL/min): reduce to ½ the dose or prolong dosing interval to 36–48hrs. Elderly: use low doses. Pregnancy. Nursing mothers: not recommended.
Concomitant dasatinib, delavirdine mesylate, cefditoren, fosamprenavir: not recommended. May alter absorption of pH-dependent drugs (eg, atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, rilpivirine). May potentiate CYP1A2 substrates (eg, tizanidine); monitor if use is needed. May give antacids concomitantly.
Headache, dizziness, constipation, diarrhea, inj site reactions; rare: CNS reactions, prolonged QT interval in renal impairment (moderate and severe).
Formerly known under the brand name Pepcid Injection.
Tabs—30, 100; Susp—50mL; Inj—contact supplier
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Oxidized Low-Density Lipoprotein May Predict Risk for Recurrent Stroke
- Inappropriate Prescribing Protocols in Parkinson Disease
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Congress Passes Bill to Fight Opioid Crisis